# IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07508761/  
OnCo record `nct07508761` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Nanjing Immunophage Biotech Co., Ltd, now recruiting.

## Summary

IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07508761 by Nanjing Immunophage Biotech Co., Ltd, with 52 participants planned, started 2026-06-16 and due to reach its primary completion in 2028-12-30. Interventions recorded: IPG7236 and Toripalimab Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07508761
- Phase: 1/2
- Setting: A Phase I/II Multicenter, Non-randomized, Open-label, Dose Escalation and Expansion Study of IPG7236 Combined With Toripalimab Treatment of Advanced Solid Tumors in Adult Patients to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity
- Sponsor: Nanjing Immunophage Biotech Co., Ltd
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT07508761: https://clinicaltrials.gov/study/NCT07508761

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [Nanjing Immunophage Biotech](https://onco.cc/companies/nanjing-immunophage-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07508761.json